The efficacy of betulinic acid in triple-negative breast cancer

SAGE Open Medicine
Daniel WeberZaynab Al-Eisawi

Abstract

The treatment of triple-negative breast cancer remains a daunting challenge with the standard-of-care treatments eventually failing due to acquired drug resistance, toxic side effects and the presence of a deregulated immune response. New treatments for overcoming these drawbacks include the use of plant extracts. In this study, the efficacy of betulinic acid, a naturally abundant phytochemical exhibiting anti-inflammatory and anti-proliferative activity, has been evaluated for the treatment of triple-negative breast cancer MDA-MB-231 and MDA-MB-468 cell lines. Furthermore, the ability of betulinic acid to inhibit angiogenesis was also determined. Here, we report that betulinic acid was able to inhibit the inflammatory response, inhibit angiogenesis and cause cell cycle arrest ultimately causing apoptosis in triple-negative breast cancer cells. Our findings support that the identification of naturally occurring anti-tumour compounds may provide a chemotherapeutic approach for the treatment of triple-negative breast cancer. Overall, our results provide a molecular basis for the ability of betulinic acid to mediate apoptosis, suppress inflammation and inhibit angiogenesis in triple-negative breast cancer cell lines.

References

Jul 10, 1999·International Journal of Cancer. Journal International Du Cancer·S FuldaK M Debatin
Dec 6, 2001·Cancer Letters·Valentina ZucoFranca Formelli
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Sep 10, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yasunari Takada, Bharat B Aggarwal
Apr 15, 2004·Bioorganic & Medicinal Chemistry Letters·Rama MukherjeeAnand C Burman
Aug 6, 2004·Endocrine Reviews·Napoleone Ferrara
Mar 1, 2005·Cytokine & Growth Factor Reviews·Simone MocellinDonato Nitti
May 3, 2005·Cytokine & Growth Factor Reviews·Marco PrestaMarco Rusnati
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lisa A CareyCharles M Perou
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bharat B AggarwalBokyung Sung
Mar 21, 2009·Molecular Cancer·Harendra S ParekhMing Q Wei
Apr 4, 2009·Nature Reviews. Cancer·Frances Balkwill
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brandon L PierceCornelia M Ulrich
Apr 13, 2010·The Breast : Official Journal of the European Society of Mastology·Catherine OakmanAngelo Di Leo
Nov 17, 2010·Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine·Daniel WeberGeoffrey M Curri
Jun 28, 2011·Journal of Biomedical Nanotechnology·Cristina A DeheleanMansoor Amiji
Jul 1, 2011·Journal of Cancer·Naoto T Ueno, Dongwei Zhang

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
PCR
PCRs
flow cytometry

Software Mentioned

SPSS

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2022 Meta ULC. All rights reserved